Samsca and Respiratory disorder - a phase IV clinical study of FDA data

Summary:

Respiratory disorder is reported as a side effect among people who take Samsca (tolvaptan), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Lasix, and have Malnutrition.

The phase IV clinical study analyzes which people have Respiratory disorder when taking Samsca. It is created by eHealthMe based on reports of 8,134 people who have side effects when taking Samsca from the FDA, and is updated regularly.

What is Samsca?

Samsca has active ingredients of tolvaptan. eHealthMe is studying from 8,139 Samsca users. Check the latest studies of Samsca.

What is Respiratory disorder?

Respiratory disorder (respiratory disease) is found to be associated with 1,540 drugs and 1,583 conditions by eHealthMe. Check the latest studies of Respiratory disorder.

On Jul, 16, 2026

8,134 people reported to have side effects when taking Samsca.
Among them, 22 people (0.27%) have Respiratory disorder.

Could Samsca cause Respiratory disorder?

Among these 22 people:

How long have people been on Samsca when they have Respiratory disorder? *

What is the gender of people who have Respiratory disorder when taking Samsca? *

female: 76.19 %
male: 23.81 %

What is the age of people who have Respiratory disorder when taking Samsca? *

What are other drugs people take besides Samsca? *

What are other side effects people have besides Respiratory disorder? *

Fever: 6 people, 27.27%
Oxygen Saturation Decreased: 5 people, 22.73%
Hepatic Function Abnormal: 5 people, 22.73%
Abdominal Pain: 4 people, 18.18%
Cytomegalovirus Viraemia (cytomegalo virus in blood stream): 4 people, 18.18%
Ileus Paralytic (obstruction of the intestine due to paralysis of the intestinal muscles): 4 people, 18.18%
Hyperglycemia (high blood sugar): 4 people, 18.18%
Pneumonia: 4 people, 18.18%
Haemoglobin Decreased: 4 people, 18.18%
Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung): 4 people, 18.18%

What are the existing conditions these people have? *

Abnormal Clotting Factor: 4 people, 18.18%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 4 people, 18.18%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 4 people, 18.18%
High Blood Pressure: 4 people, 18.18%
Hyperglycemia (high blood sugar): 4 people, 18.18%
Hypoalbuminaemia (levels of albumin in blood serum are abnormally low): 4 people, 18.18%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 4 people, 18.18%
Ileus Paralytic (obstruction of the intestine due to paralysis of the intestinal muscles): 4 people, 18.18%
Insomnia (sleeplessness): 4 people, 18.18%
Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking): 4 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Samsca and have Respiratory disorder?

- Check whether Respiratory disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Samsca:

Samsca (8,139 reports)

Browse all side effects of Samsca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Respiratory disorder:

Respiratory disorder (1,540 drugs)

Browse all the conditions that are associated with Respiratory disorder:

Respiratory disorder (1,583 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tolvaptan (the active ingredients of Samsca) and Samsca (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.